Fate Of Speedel’s Diabetic Nephropathy Drug May Be Clearer Mid-Year 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
DSMB halts Phase III trial of SPP301 due to an imbalance of fluid retention in patients in the study arms.